Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

NCT05277766 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Peritoneal Carcinomatosis
Peritoneal Metastases
Colorectal Cancer
Small Bowel Cancer
Appendix Cancer
Gastric Cancer
Pancreatic Cancer
Bile Duct Cancer

Interventions

DRUG: PIPAC with Nal-IRI

Sponsor

University Hospital, Ghent

Collaborators

[object Object]
[object Object]